Michel Duval is a pediatrician and hematologist-oncologist, specializing in hematopoietic transplantation and holds a master’s degree in immunology. Trained in Paris, he joined CHU Sainte-Justine in 2001. For 10 years, he was the medical director of the Hematopoietic Transplant and Cell Therapy Program at the Charles-Bruneau Cancer Centre at CHU Sainte-Justine. He is a full professor at the Université de Montréal.

 

For more than 25 years, his research work has focused on immunotherapy for childhood cancers, more specifically on the exploitation of innate immunity after transplantation: Natural Killer (NK) cells and their natural activators, plasmacytoid dendritic cells. A translational researcher, he has published both laboratory and clinical research. He is Director of the Laboratoire de Recherche sur la Greffe de Sang de Cordon at the Centre Charles-Bruneau, supported by the Fonds de Recherche du Québec-Santé, the Canadian Institutes of Health Research, C17, the Fondation Charles-Bruneau, BioCanRx and the Oncopole LeadAction Fund. He is part of a team of clinical researchers who are developing clinical trials of immunotherapy for childhood cancer, focusing on hematopoietic transplantation.

 

The difficult situations faced by his patients and their families have motivated him to pursue a second field of research and teaching: ethics and palliative care. He is a professor at the Master's Degree in Clinical Ethics at the Université de Montréal, a member of the Palliative Care Consultation Unit and the Clinical Ethics Unit at CHU Sainte-Justine.

 

Dr. Duval heads the Hemato-Oncology Division at CHU Sainte-Justine. He is the co-author of more than 100 scientific articles and a reference book on transplant decision support for families that printed 35,000 copies in three editions, recently translated into English with the support of Cell Therapy Transplant Canada.